BRISTOL MYERS SQUIBB CO shareholders Q3 2023

BRISTOL MYERS SQUIBB CO's ticker is BMY and the CUSIP is 110122108. A total of 2,332 filers reported holding BRISTOL MYERS SQUIBB CO in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.

BRISTOL MYERS SQUIBB CO shareholders Q3 2023
NameSharesValueWeighting ↓
Psagot Value Holdings Ltd. / (Israel) 28,187$1,6380.83%
SANDERS MORRIS HARRIS LLC 70,114$4,038,5830.83%
Legacy Bridge, LLC 20,058$1,164,1670.83%
OPTIONS SOLUTIONS, LLC 13,104$760,5390.82%
Mechanics Bank Trust Department 84,998$4,933,2830.82%
American Assets Investment Management, LLC 127,000$7,371,0800.82%
Cypress Capital Group 98,122$5,694,9950.82%
HYMAN CHARLES D 217,669$12,634,0000.82%
Old North State Trust, LLC 18,175$1,0550.82%
GARRISON POINT ADVISORS, LLC 18,276$1,060,7390.82%
DEAN INVESTMENT ASSOCIATES, LLC 85,750$4,976,9300.82%
Greystone Financial Group, LLC 56,250$3,264,7680.82%
Donald L. Hagan, LLC 23,378$1,356,8590.81%
EADS & HEALD WEALTH MANAGEMENT 26,632$1,5460.81%
Radnor Capital Management, LLC 69,906$4,0570.81%
Ceeto Capital Group, LLC 28,600$1,6600.80%
NEVILLE RODIE & SHAW INC 154,553$8,9700.80%
PARADIGM ASSET MANAGEMENT CO LLC 48,308$2,803,7960.79%
Talbot Financial, LLC 78,448$4,553,1220.79%
D L CARLSON INVESTMENT GROUP INC 67,559$3,921,1050.79%
About BRISTOL MYERS SQUIBB CO

Bristol Myers Squibb Co. is a leading pharmaceutical company that has been in operation for over a century. The company is known for its innovative research and development of drugs that treat a wide range of diseases, including cancer, cardiovascular disease, and HIV/AIDS.

One of the company's most significant achievements is the development of Opdivo, a drug that has revolutionized the treatment of cancer. Opdivo is a checkpoint inhibitor that helps the immune system fight cancer cells. The drug has been approved for the treatment of several types of cancer, including melanoma, lung cancer, and renal cell carcinoma.

Bristol Myers Squibb Co. has also been at the forefront of the fight against HIV/AIDS. The company's drug, Reyataz, is a protease inhibitor that is used in combination with other drugs to treat HIV/AIDS. The drug has been instrumental in helping people with HIV/AIDS live longer, healthier lives.

The company's commitment to innovation and research has made it a leader in the pharmaceutical industry. Bristol Myers Squibb Co. has a strong pipeline of drugs in development, including treatments for cancer, cardiovascular disease, and immunology.

In conclusion, Bristol Myers Squibb Co. is a pharmaceutical company that has made significant contributions to the treatment of diseases such as cancer and HIV/AIDS. The company's commitment to innovation and research has made it a leader in the industry, and its pipeline of drugs in development promises to bring new treatments to patients in need.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BRISTOL MYERS SQUIBB CO's shareholders in Q3 2023. To view BRISTOL MYERS SQUIBB CO's shareholder history, click here.